SCHEMBL2365076

SCHEMBL2365076

Cc1cn(-c2cc(CNc3ccc(C)c(NC(=O)c4csc5c(N(C(=O)O)C6CC6)ncnc45)c3)cc(C(F)(F)F)c2)cn1

nearest known ligand 0.44

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.44
POLB P06746 1/20 0.44
RECQL P46063 1/20 0.44
CSF1R P07333 1/20 0.43
EPHB2 P29323 1/20 0.42
RAF1 P04049 1/20 0.40
MAPT P10636 1/20 0.40
HCK P08631 1/20 0.40
NR2C2 P49116 1/20 0.40
BTK Q06187 1/20 0.40
NR2E1 Q9Y466 7/20 0.39
BRAF P15056 2/20 0.39
ABL1 P00519 3/20 0.38
BCR P11274 2/20 0.38
SRC P12931 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2359007 0.86 CSF1R (0.47) KDM4EPOLBRECQLCSF1REPHB2
SCHEMBL2357417 0.85 ABL1 (0.47) KDM4EPOLBRECQLCSF1REPHB2
SCHEMBL2358401 0.84 BRAF (0.46) KDM4EPOLBRECQLCSF1REPHB2
SCHEMBL2359059 0.79 EPHB2 (0.50) CSF1REPHB2RAF1HCKNR2C2
SCHEMBL19057073 0.78 ABL1 (0.49) RAF1NR2E1BRAFABL1BCR
SCHEMBL2357420 0.76 ABL1 (0.51) CSF1REPHB2RAF1HCKNR2C2
SCHEMBL12432449 0.76 CSF1R (0.58) KDM4EPOLBRECQLCSF1REPHB2
SCHEMBL14110085 0.76 ABL1 (0.56) KDM4EPOLBRECQLCSF1REPHB2
SCHEMBL12433883 0.76 CSF1R (0.59) KDM4EPOLBRECQLCSF1REPHB2
SCHEMBL2359009 0.75 EPHB2 (0.53) KDM4EPOLBRECQLCSF1REPHB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2528925-B1 THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES HANMI SCIENCE CO LTD (KR) 2017-07-05 EP claimed
US-8999973-B2 Thieno[3,2-d]pyrimidine derivatives having inhibitory activity on protein kinases HANMI SCIENCE CO., LTD (KR) 2015-04-07 US claimed
US-20130053370-A1 THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES HANMI SCIENCE CO., LTD. (KR) 2013-02-28 US claimed
EP-2528925-A2 THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES Hanmi Science Co., Ltd. (KR) 2012-12-05 EP claimed
WO-2011093684-A2 THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES HANMI HOLDINGS CO., LTD. (KR) 2011-08-04 WO claimed
EP-2528925-B1 THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES HANMI SCIENCE CO LTD (KR) 2017-07-05 EP disclosed
US-8999973-B2 Thieno[3,2-d]pyrimidine derivatives having inhibitory activity on protein kinases HANMI SCIENCE CO., LTD (KR) 2015-04-07 US disclosed
US-20130053370-A1 THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES HANMI SCIENCE CO., LTD. (KR) 2013-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130053370-A1 THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES CDK2, TK1, DTYMK KDM4E 2448/4885POLB 1235/4885RECQL 1472/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.